Acumen Pharmaceuticals (ABOS) Total Current Liabilities (2021 - 2026)

Acumen Pharmaceuticals has reported Total Current Liabilities for 6 years, with the latest figure at $29.2 million in Q1 2026.

• Quarterly Total Current Liabilities rose 51.33% year-over-year to $29.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.2 million (up 51.33% YoY) and the FY2025 annual result came in at $30.0 million, up 8.69% from the prior year.
• Total Current Liabilities slipped to $29.2 million in Q1 2026 per ABOS's latest filing, from $30.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $30.0 million in Q4 2025 and troughed at $3.9 million in Q1 2022.
• A 5-year average of $15.1 million and a median of $13.0 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities slipped 7.79% in 2023, then soared 226.57% in 2024.
• Over 5 years, Total Current Liabilities stood at $7.8 million in 2022, then soared by 66.04% to $13.0 million in 2023, then surged by 112.84% to $27.6 million in 2024, then gained by 8.69% to $30.0 million in 2025, then declined by 2.59% to $29.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $29.2 million, $30.0 million, and $22.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.